<DOC>
	<DOCNO>NCT00321815</DOCNO>
	<brief_summary>To assess efficacy safety PF-3512676 administer combination erlotinib patient advance EGFR-positive non-small cell lung cancer failure least one prior chemotherapy regimen .</brief_summary>
	<brief_title>Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Advanced , EGFRpositive NSCLC ECOG Performance Status 0 , 1 2 Measurable disease Known CNS metastasis Preexisting autoimmune antibody mediate disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>advanced carcinoma non-small cell lung EGFR positive Erlotinib Tarceva PF-3512676 Phase II immunotherapy immune modulator</keyword>
</DOC>